Autopsy report · NCT02889211

Brain Function in Depression and Insulin Resistance

“Principal Investigator Left University”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 4 months before it stopped.
• 42 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

University of Pittsburgh

Sponsor type

University, hospital or other

Conditions

Depression; Insulin Resistance

Interventions

Gambling Task

Participants

42

Sites

1

Countries

United States

Trials that died the same way

• Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.
  “Principal Investigator left institution” (93% match in meaning)
• Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
  “Principal investigator left the institution” (92% match in meaning)
• Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM
  “Principal Investigator has left the institution” (91% match in meaning)
• Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders
  “the Principal Investigator left the institution” (90% match in meaning)
• Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
  “Original Principal Investigator left the institution.” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.